Literature DB >> 29490284

Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach.

Raghavan Chinnadurai1, Devi Rajan2, Muna Qayed2, Dalia Arafat3, Marco Garcia4, Yifei Liu5, Subra Kugathasan2, Larry J Anderson2, Greg Gibson3, Jacques Galipeau6.   

Abstract

Assays that can characterize MSC immune potency need to be identified for use in advanced clinical trials. MSCs possess a number of putative regenerative and immunomodulatory properties, and an assay matrix approach may best capture involved effector pathways. We have tested two assay systems to measure the potency of MSCs derived from human subjects: MSC secretome analysis and a quantitative RNA-based array for genes specific to immunomodulatory and homing properties of MSCs. Secretome analysis identified a unique cytokine signature that is upregulated by MSCs or downregulated in responder PBMCs and correlated with T cell suppression. Use of interferon-γ as a surrogate for the action of activated PBMCs on MSCs served as an alternative for the use of human PBMCs as responder cells in a potency assay. Our approach and results define and simplify the multifunctional or matrix responses of MSCs and may serve as a platform for robust potency analysis.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PBMCs; assay matrix; interferon-γ; mesenchymal stromal cells; secretome; transcriptome

Mesh:

Substances:

Year:  2018        PMID: 29490284      PMCID: PMC5855117          DOI: 10.1016/j.celrep.2018.02.013

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  48 in total

1.  Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency.

Authors:  Bahey Salem; Samantha Miner; Nancy F Hensel; Minoo Battiwalla; Keyvan Keyvanfar; David F Stroncek; Adrian P Gee; Patrick J Hanley; Catherine M Bollard; Sawa Ito; A John Barrett
Journal:  Cytotherapy       Date:  2015-09-28       Impact factor: 5.414

2.  IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells.

Authors:  Raghavan Chinnadurai; Ian B Copland; Seema R Patel; Jacques Galipeau
Journal:  J Immunol       Date:  2014-01-08       Impact factor: 5.422

3.  The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria.

Authors:  Jacques Galipeau; Mauro Krampera
Journal:  Cytotherapy       Date:  2015-02       Impact factor: 5.414

4.  MSC-based product characterization for clinical trials: an FDA perspective.

Authors:  Michael Mendicino; Alexander M Bailey; Keith Wonnacott; Raj K Puri; Steven R Bauer
Journal:  Cell Stem Cell       Date:  2014-02-06       Impact factor: 24.633

5.  Characterization of mesenchymal stromal cells: potency assay development.

Authors:  Peiman Hematti
Journal:  Transfusion       Date:  2016-04       Impact factor: 3.157

6.  Mesenchymal stem/stromal cells precondition lung monocytes/macrophages to produce tolerance against allo- and autoimmunity in the eye.

Authors:  Jung Hwa Ko; Hyun Ju Lee; Hyun Jeong Jeong; Mee Kum Kim; Won Ryang Wee; Sun-Ok Yoon; Hosoon Choi; Darwin J Prockop; Joo Youn Oh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-22       Impact factor: 11.205

7.  Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity.

Authors:  Ian B Copland; Muna Qayed; Marco A Garcia; Jacques Galipeau; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-03       Impact factor: 5.742

8.  Function of Cryopreserved Mesenchymal Stromal Cells With and Without Interferon-γ Prelicensing is Context Dependent.

Authors:  Anthony J Burand; Oliver W Gramlich; Alex J Brown; James A Ankrum
Journal:  Stem Cells       Date:  2016-11-10       Impact factor: 6.277

9.  Cell senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia model.

Authors:  Juan Carlos Sepúlveda; María Tomé; María Eugenia Fernández; Mario Delgado; Judith Campisi; Antonio Bernad; Manuel A González
Journal:  Stem Cells       Date:  2014-07       Impact factor: 6.277

10.  Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing.

Authors:  Moïra François; Ian B Copland; Shala Yuan; Raphaëlle Romieu-Mourez; Edmund K Waller; Jacques Galipeau
Journal:  Cytotherapy       Date:  2011-10-27       Impact factor: 5.414

View more
  60 in total

1.  Enabling mesenchymal stromal cell immunomodulatory analysis using scalable platforms.

Authors:  Evelyn Kendall Williams; José R García; Robert G Mannino; Rebecca S Schneider; Wilbur A Lam; Andrés J García
Journal:  Integr Biol (Camb)       Date:  2019-04-01       Impact factor: 2.192

Review 2.  Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.

Authors:  Jacques Galipeau; Luc Sensébé
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

Review 3.  Is Stem Cell Commerce in Small Animal Therapies Scientifically and Morally Justified?

Authors:  Luane Lopes Pinheiro; Ana Rita de Lima; Érika Branco
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

Review 4.  Effects of Physical, Chemical, and Biological Stimulus on h-MSC Expansion and Their Functional Characteristics.

Authors:  David A Castilla-Casadiego; Ana M Reyes-Ramos; Maribella Domenech; Jorge Almodovar
Journal:  Ann Biomed Eng       Date:  2019-11-08       Impact factor: 3.934

5.  Potency Analysis of Mesenchymal Stromal Cells Using a Phospho-STAT Matrix Loop Analytical Approach.

Authors:  Raghavan Chinnadurai; Augustine Rajakumar; Andrew J Schneider; Wade A Bushman; Peiman Hematti; Jacques Galipeau
Journal:  Stem Cells       Date:  2019-06-03       Impact factor: 6.277

Review 6.  Cell Therapy-a Basic Science Primer for the Sports Medicine Clinician.

Authors:  Bijan Dehghani; Scott Rodeo
Journal:  Curr Rev Musculoskelet Med       Date:  2019-12

7.  Molecular Genetic and Immune Functional Responses Distinguish Bone Marrow Mesenchymal Stromal Cells from Hepatic Stellate Cells.

Authors:  Raghavan Chinnadurai; Jenna Sands; Devi Rajan; Xiao Liu; Dalia Arafat; Rahul Das; Frank A Anania; Greg Gibson; Tatiana Kisseleva; Jacques Galipeau
Journal:  Stem Cells       Date:  2019-05-09       Impact factor: 6.277

Review 8.  Manufacturing of primed mesenchymal stromal cells for therapy.

Authors:  James Q Yin; Jun Zhu; James A Ankrum
Journal:  Nat Biomed Eng       Date:  2019-01-28       Impact factor: 25.671

9.  Use of MSCs and MSC-educated macrophages to mitigate hematopoietic acute radiation syndrome.

Authors:  Raghavan Chinnadurai; Matthew H Forsberg; John A Kink; Peiman Hematti; Christian M Capitini
Journal:  Curr Stem Cell Rep       Date:  2020-08-08

10.  Dose and duration of interferon γ pre-licensing interact with donor characteristics to influence the expression and function of indoleamine-2,3-dioxygenase in mesenchymal stromal cells.

Authors:  Devlin T Boyt; Lauren K Boland; Anthony J Burand; Alex J Brown; James A Ankrum
Journal:  J R Soc Interface       Date:  2020-06-17       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.